Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy Review uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Genetic Markers
  • Leukemia, Myeloid, Acute

abstract

  • Acute myeloid leukemia is a heterogeneous disease. Standard treatments may be applied to biologically distinct subgroups, resulting in different treatment outcomes. The concept of risk-adapted therapy allows for recognition of this biologic diversity by incorporating key biologic features, such as cytogenetic and molecular markers, when formulating treatment regimens and investigating emerging targeted therapies based on disease characteristics.

publication date

  • November 2008

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 19176197

Additional Document Info

start page

  • 995

end page

  • 1002

volume

  • 6

number

  • 10